Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma

Oncotarget

Volumn 6, Issue 23, 2015, Pages 19891-19906

  Peng, Chien Hua ^a   Liao, Chun Ta ^a   Ng, Ka Pou ^b   Tai, An Shun ^b   Peng, Shih Chi ^a   Yeh, Jen Pao ^b   Chen, Shu Jen ^c   Tsao, Kuo Chien ^a   Yen, Tzu Chen ^a   Hsieh, Wen Ping ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Biomarker; Clinically actionable genes; Copy number alteration; Oral cavity squamous cell carcinoma; Ultradeep targeted sequencing

Indexed keywords

CISPLATIN; TUMOR MARKER;

AKT GENE; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; FEMALE; FGFR1 GENE; FOXO GENE; GENE; GENE AMPLIFICATION; GENE CLUSTER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PROCEDURES; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; NECK DISSECTION; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PI3K GENE; PIK3CA GENE; PREDICTION; RECURRENCE RISK; RISK FACTOR; SECOND CANCER; SIGNAL TRANSDUCTION; STATISTICAL MODEL; ULTRA DEEP TARGETED SEQUENCING; CARCINOMA, SQUAMOUS CELL; CHI SQUARE DISTRIBUTION; DISEASE COURSE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK NEOPLASMS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; MORTALITY; MOUTH NEOPLASMS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939237496     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4336     Document Type: Article

References (62)

1. Trivedy CR, Craig G and Warnakulasuriya S. The oral health consequences of chewing areca nut. Addiction biology. 2002; 7:115-125.
2. India Project Team of the International Cancer Genome C. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups. Nature communications. 2013; 4:2873.
3. Majumder PP. Mutational landscape of gingivo-buccal oral cancer: new cancer genes and molecular subgroups identified. Molecular cytogenetics. 2014; 7(Suppl 1 Proceedings of the International Conference on Human):I8.
4. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhang CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, Getz G, et al. Pan-cancer patterns of somatic copy number alteration. Nature genetics. 2013; 45:1134-1140.
5. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, Zhao M, Ortega Alves MV, Chang K, Drummond J, Cortez E, Xie TX, Zhang D, Chung W, Issa JP, Zweidler-McKay PA, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer discovery. 2013; 3:770-781.
6. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes ML, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333:1157-1160.
7. Leemans CR, Braakhuis BJ and Brakenhoff RH. The molecular biology of head and neck cancer. Nature reviews Cancer. 2011; 11:9-22.
8. Xu C, Wang P, Liu Y, Zhang Y, Fan W, Upton MP, Lohavanichbutr P, Houck JR, Doody DR, Futran ND, Zhao LP, Schwartz SM, Chen C and Mendez E. Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma. PLoS genetics. 2013; 9:e1003169.
9. Salahshourifar I, Vincent-Chong VK, Kallarakkal TG and Zain RB. Genomic DNA copy number alterations from precursor oral lesions to oral squamous cell carcinoma. Oral oncology. 2014; 50:404-412.
10. Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, Juang JL, Tsai CY, Chen TC, Chuang YJ, Tang CY, Hsieh WP and Yen TC. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PloS one. 2011; 6:e23452.
11. Micke P, Edlund K, Holmberg L, Kultima HG, Mansouri L, Ekman S, Bergqvist M, Scheibenflug L, Lamberg K, Myrdal G, Berglund A, Andersson A, Lambe M, Nyberg F, Thomas A, Isaksson A, et al. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011; 6:1833-1840.
12. Russnes HG, Vollan HK, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, Sorlie T, Borgen E, Rye IH, Langerod A, Chin SF, Teschendorff AE, Stephens PJ, Maner S, Schlichting E, Baumbusch LO, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Science translational medicine. 2010; 2:38ra47.
13. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD and Luthra R. Clinical validation of a nextgeneration sequencing screen for mutational hotspots in 46 cancer-related genes. The Journal of molecular diagnostics : JMD. 2013; 15:607-622.
14. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD and Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. The Journal of molecular diagnostics: JMD. 2013; 15:623-633.
15. Gaykalova DA, Mambo E, Choudhary A, Houghton J, Buddavarapu K, Sanford T, Darden W, Adai A, Hadd A, Latham G, Danilova LV, Bishop J, Li RJ, Westra WH, Hennessey P, Koch WM, et al. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PloS one. 2014; 9:e93102.
16. Sathirapongsasuti JF, Lee H, Horst BA, Brunner G, Cochran AJ, Binder S, Quackenbush J and Nelson SF. Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV. Bioinformatics. 2011; 27:2648-2654.
17. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research. 2012; 22:568-576.
18. Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou S, Wood NW, Hambleton S, Burns SO, Thrasher AJ, Kumararatne D, Doffinger R and Nejentsev S. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics. 2012; 28:2747-2754.
19. Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, Janoueix-Lerosey I, Delattre O and Barillot E. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012; 28:423-425.
20. Krumm N, Sudmant PH, Ko A, O'Roak BJ, Malig M, Coe BP, Project NES, Quinlan AR, Nickerson DA and Eichler EE. Copy number variation detection and genotyping from exome sequence data. Genome research. 2012; 22:1525-1532.
21. Coin LJ, Cao D, Ren J, Zuo X, Sun L, Yang S, Zhang X, Cui Y, Li Y, Jin X and Wang J. An exome sequencing pipeline for identifying and genotyping common CNVs associated with disease with application to psoriasis. Bioinformatics. 2012; 28:i370-i374.
22. McVean G. A genealogical interpretation of principal components analysis. PLoS genetics. 2009; 5:e1000686.
23. Fromer M, Moran JL, Chambert K, Banks E, Bergen SE, Ruderfer DM, Handsaker RE, McCarroll SA, O'Donovan MC, Owen MJ, Kirov G, Sullivan PF, Hultman CM, Sklar P and Purcell SM. Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. American journal of human genetics. 2012; 91:597-607.
24. Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG and Gorringe KL. CONTRA: copy number analysis for targeted resequencing. Bioinformatics. 2012; 28:1307-1313.
25. Boeva V, Popova T, Lienard M, Toffoli S, Kamal M, Le Tourneau C, Gentien D, Servant N, Gestraud P, Rio Frio T, Hupe P, Barillot E and Laes JF. Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics. 2014;30:3443-50.
26. Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H and Frazer KA. Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast cancer research : BCR. 2013; 15:R115.
27. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ and Yen TC. Survival in squamous cell carcinoma of the oral cavity: differences between pT4 N0 and other stage IVA categories. Cancer. 2007; 110:564-571.
28. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ and Yen TC. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Annals of surgical oncology. 2008; 15:915-922.
29. Liao CT, Huang SF, Chen IH, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Cheng AJ and Yen TC. Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. Annals of surgical oncology. 2009; 16:159-170.
30. Liao CT, Lee LY, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, Wang HM, Ng SH and Yen TC. Outcome analysis of patients with oral cavity cancer and extracapsular spread in neck lymph nodes. International journal of radiation oncology, biology, physics. 2011; 81:930-937.
31. Murugan AK, Munirajan AK and Tsuchida N. Genetic deregulation of the PIK3CA oncogene in oral cancer. Cancer letters. 2013; 338:193-203.
32. Haibe-Kains B, Desmedt C, Sotiriou C and Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics. 2008; 24:2200-2208.
33. Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, Lin CY, Fan KH, Wang HM, Huang SF, Chen IH, Kang CJ, Ng SH, Yang SL, Tsao KC, Chang YL, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PloS one. 2012; 7:e40767.
34. Goot-Heah K, Kwai-Lin T, Froemming GR, Abraham MT, Nik Mohd Rosdy NM and Zain RB. Human papilloma virus 18 detection in oral squamous cell carcinoma and potentially malignant lesions using saliva samples. Asian Pacific journal of cancer prevention: APJCP. 2012; 13:6109-6113.
35. Zhu C, Ling Y, Dong C, Zhou X and Wang F. The relationship between oral squamous cell carcinoma and human papillomavirus: a meta-analysis of a Chinese population (1994-2011). PloS one. 2012; 7:e36294.
36. Chiosea SI, Grandis JR, Lui VW, Diergaarde B, Maxwell JH, Ferris RL, Kim SW, Luvison A, Miller M and Nikiforova MN. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC cancer. 2013; 13:602.
37. Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Lichter P and Joos S. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral oncology. 2007; 43:60-66.
38. Choi S and Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. Journal of dental research. 2008; 87:14-32.
39. Martin-Ezquerra G, Salgado R, Toll A, Gilaberte M, Baro T, Alameda Quitllet F, Yebenes M, Sole F, Garcia-Muret M, Espinet B and Pujol RM. Multiple genetic copy number alterations in oral squamous cell carcinoma: study of MYC, TP53, CCDN1, EGFR and ERBB2 status in primary and metastatic tumours. The British journal of dermatology. 2010; 163:1028-1035.
40. Mendes RA. Oncogenic Pathways in the Development of Oral Cancer. Journal of Carcinogenesis&Mutagenesis. 2012; 3:2.
41. Sparano A, Quesnelle KM, Kumar MS, Wang Y, Sylvester AJ, Feldman M, Sewell DA, Weinstein GS and Brose MS. Genome-wide profiling of oral squamous cell carcinoma by array-based comparative genomic hybridization. The Laryngoscope. 2006; 116:735-741.
42. Kerdpon D, Sriplung H and Kietthubthew S. Expression of p53 in oral squamous cell carcinoma and its association with risk habits in southern Thailand. Oral oncology. 2001; 37:553-557.
43. Topcu Z, Chiba I, Fujieda M, Shibata T, Ariyoshi N, Yamazaki H, Sevgican F, Muthumala M, Kobayashi H and Kamataki T. CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis. 2002; 23:595-598.
44. Shin KH, Kim JM, Rho KS, Park KH, Oh JE and Min BM. Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. International journal of oncology. 2002; 21:997-1001.
45. Pande P, Mathur M, Shukla NK and Ralhan R. pRb and p16 protein alterations in human oral tumorigenesis. Oral oncology. 1998; 34:396-403.
46. Wang X, Sun W, Bai J, Ma L, Yu Y, Geng J, Qi J, Shi Z and Fu S. Growth inhibition induced by transforming growth factor-beta1 in human oral squamous cell carcinoma. Molecular biology reports. 2009; 36:861-869.
47. Han G and Wang XJ. Roles of TGFbeta signaling Smads in squamous cell carcinoma. Cell&bioscience. 2011; 1:41.
48. Stoicanescu D, Andreescu N, Belengeanu A, Meszaros N and Cornianu M. Assessment of p53 and HER-2/ neu genes status and protein products in oral squamous cell carcinomas. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2013; 54:1107-1113.
49. Fang Z, Xiong Y, Li J, Liu L, Zhang W, Zhang C and Wan J. APC gene deletions in gastric adenocarcinomas in a Chinese population: a correlation with tumour progression. Clinical&translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012; 14:60-65.
50. Bogaert J and Prenen H. Molecular genetics of colorectal cancer. Annals of gastroenterology: quarterly publication of the Hellenic Society of Gastroenterology. 2014; 27:9-14.
51. Nobusawa S, Stawski R, Kim YH, Nakazato Y and Ohgaki H. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study. Neuropathology : official journal of the Japanese Society of Neuropathology. 2011; 31:583-588.
52. Blom T, Roselli A, Hayry V, Tynninen O, Wartiovaara K, Korja M, Nordfors K, Haapasalo H and Nupponen NN. Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. Journal of neuro-oncology. 2010; 97:217-224.
53. Iozzo RV and Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. Journal of cellular and molecular medicine. 2011; 15:1013-1031.
54. Zhang X, Tang N, Hadden TJ and Rishi AK. Akt, FoxO and regulation of apoptosis. Biochimica et biophysica acta. 2011; 1813:1978-1986.
55. Akinleye A, Avvaru P, Furqan M, Song Y and Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. Journal of hematology&oncology. 2013; 6:88.
56. Bhutani J, Sheikh A and Niazi AK. Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infectious agents and cancer. 2013; 8:49.
57. Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, Xu Y, Tang L, Wang H, Liu YJ, Yin X, Ji Q and Yu DH. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. Journal of translational medicine. 2013; 11:241.
58. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ and Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell reports. 2014; 6:377-387.
59. Dienstmann R, Rodon J, Serra V and Tabernero J. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Molecular cancer therapeutics. 2014; 13:1021-1031.
60. Melchiorri C, Cattini L, Lalli E, Campobassi A, Marchetti C and Facchini A. DNA ploidy analysis of squamous cell carcinomas of the oral and maxillofacial region: clinical and pathologic correlations. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 1996; 82:308-314.
61. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL and Rosati RA. Evaluating the yield of medical tests. Jama. 1982; 247:2543-2546.
62. Harrell FE, Jr., Lee KL and Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in medicine. 1996; 15:361-387.